Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START2: Tecemotide in Stage III NSCLC
NCT02049151Phase 3Terminated
- Sponsor
- EMD Serono
- Start
- Mar 2014
- Primary completion
- Jul 2015
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tecemotide with Placebo (2 arms). Primary endpoint: Overall Survival at 16 months. Started Mar 2014; status: terminated.
02
Drugs
tecemotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02049151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049151.